Detection of endocrine disorders in young children with multi-transfused thalassemia major

Ramadan A. Mahmoud1*, Ashraf Khodeary2 and Marwa S. Farhan3

Abstract

Background: Beta thalassemia major (TM) is the most common inherited genetic disorder worldwide. Patients are at risk of iron overload, which leads to various forms of tissue damage, including endocrinopathies. The aim of this study was to evaluate the prevalence and risk factors of endocrine disorders in young patients with multi-transfused TM receiving iron chelation therapy.

Methods: The inclusion criteria included all known cases of TM according to hemoglobin electrophoresis data, aged 12 years or younger, during the study period. The patient’s age, gender, parent’s consanguinity, clinical examination, and types of iron chelating agents used were recorded. Serum ferritin level, complete blood count (CBC), blood glucose homeostasis, thyroid, and parathyroid functions were determined.

Results: One hundred twenty patients met the inclusion criteria; 70% of them had malnutrition. The presence of endocrine disorders was observed in 28/120 (23.33%) patients. The most common endocrine disorders were thyroid disorders, either subclinical or clinical hypothyroidism in 11/120 (9.17%) patients, followed by abnormalities in glucose homeostasis 9/120 (7.5%). The prevalence of impaired glucose tolerance, impaired fasting glucose, and diabetes mellitus in the present study was 5 (4.17%), 4 (3.33%), and 0 (0%), respectively, while the least frequent endocrine disorder seen in our patients was hypoparathyroidism in 8/120 (6.66%). We noted that high serum ferritin levels and poor patient compliance to therapy were significantly associated with increased endocrine disorders (OR 0.98, 95% CI 0.96–0.99, \( P = 0.003 \) and OR 0.38, 95% CI 0.16:0.93, \( P = 0.03 \), respectively). Combined chelating iron agents significantly decreased the prevalence of endocrine disorders when compared with monotherapy (OR 0.40, 95% CI 0.16:0.97, \( P = 0.04 \)).

Conclusion: Endocrine disorders could occur in TM patients early before or equal to 12 years of life in about one-fourth of the patients. A high serum ferritin level and poor patient compliance to therapy were significantly associated with increased endocrine disorders. Combined iron-chelating agents were associated with a decreased prevalence of endocrine disorders when compared with monotherapy.

Keywords: Thalassemia major, Endocrine disorders, Young children, Iron chelating agent

* Correspondence: ramadan.aboelhassan@yahoo.com; ramadan_aboelhassan@med.sohag.edu.eg
1Department of Paediatrics, Faculty of Medicine, Sohag University, Sohag 82524, Egypt
2Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

Beta thalassemia major (TM) is an autosomal recessive inherited disorder caused by decreased or absent β-globin chain production. There are 200 mutations linked with a TM phenotype that affect the stages of β-globin gene expression [1]. TM is the most prevalent monogenic disorder in the world, and the incidence rate is higher in the Middle East [2]. TM is the most common chronic hemolytic anemia in Egypt. It constitutes a major health problem with an estimated carrier rate of 9–10% [3].

TM brings long-term extravascular hemolysis, which increases iron absorption in the intestinal tract. Combined with multiple blood transfusions, this could lead to iron overload and an increased amount of iron in the tissue, which can cause progressive tissue damage in the liver, heart, endocrine glands, and other organs by generating hydroxy radicals and oxidative stress [4–6].

Treatment of TM is always individualized and modified according to the patient’s conditions. Conventional treatment consists of regular transfusions, an iron chelating agent, splenectomy, supportive therapies, and psychological support [7]. Non-conventional treatment includes hematopoietic stem cell transplantation, which remains the only curative treatment, fetal hemoglobin modulation, and gene therapy [8, 9]. Furthermore, the life expectancy and the quality of life of TM has improved remarkably over the last decades following optimized transfusion programs and improvements in chelation therapy [10, 11]. However, patients still experience a range of problems, particularly in relation to their growth, development, malnutrition, transfusion-transmitted infections, and tissue damage such as in the liver, heart, and endocrine system. These factors may contribute to the morbidity and mortality of these patients [12].

Endocrinopathies are common in patients with TM despite parenteral and oral iron chelation therapy. A majority of studies have focused on endocrine disorders in the adult population over 12 years of age. Many of these reports are from the Mediterranean area, and few studies have been conducted in children and young adults from Asian populations [13–17]. These studies researched the efficacy of TM treatments in preventing endocrine disorders. There are no studies in the literature describing the possibility of endocrine disorders that may start early in TM patients before 12 years of age. The aim of this study was to evaluate the prevalence of clinical and subclinical hypothyroidism, hypercalcemia, hyperphosphatemia, and impaired glucose metabolism in patients with TM who were 12 years of age or younger receiving oral or parental iron chelation therapy.

**Materials and methods**

**Subject and data collection**

In this cross-sectional study, we analyzed blood samples taken from 120 transfusion-dependent TM children age 12 years or younger during the period from May 2017 to May 2019 in the Pediatrics Departments, Faculty of Medicine, Sohag University, Egypt. Ethical approval for the study was obtained from the Research Committee of the Medical Faculty, Sohag University (Number 612, 2017), and written informed consent was obtained from all guardians/parents of the children prior to allocation of the children to the study.

The inclusion criteria included all known children with TM according to hemoglobin electrophoresis data aged 12 years or younger. Completed laboratory investigations were mandatory for inclusion the study. A clinical history and full examination were performed for each child included in the study. All patients were under a regular transfusion program with the aim of maintaining pre-transfusion hemoglobin levels above 9 g/dl. Hemophilic children and children with other types of hemolytic anemias, such as α-thalassemia, sickle cell anemia, and spherocytosis were excluded from the study.

A detailed history was taken with emphasis on personal history, parent consanguinity, family history of TM, family history of endocrine disorders, number of blood transfusions/month, and duration of disease, and a full clinical examination was performed, including anthropometric measurements, pallor, jaundice, hepatomegaly, cirrhotic manifestations, splenectomy, and cardiac examination. As regards the types of iron chelating agents used, we started with deferasirox as initial therapy when the serum ferritin level was greater than or equal to 1000 μg/L. However, if deferasirox was not available or ineffective, deferoxamine was used or added as adjuvant therapy according to the serum ferritin level.

For assessment of nutritional status, weight, length, body mass index (BMI) were reordered. World Health Organization (WHO) Z-score (standard deviation scores) for BMI (weight in kilograms divided by the square of height in meters) with using a cut-points of < −2.0, > 1.0, > 2.0 and > 3.0 were used to classify malnutrition, risk of overweight, overweight, and obese, respectively [18].

**Laboratory investigations**

Form all patients, 8 ml venous blood was obtained by venipuncture and was divided into two tubes, 2 ml blood in an EDTA vacutainer for complete blood count (CBC) and glycosylated hemoglobin (HbA1C) and 6 ml blood in two plane vacutainers for serum ferritin level, thyroid stimulating hormone (TSH), free thyroxine 3 (FT3), free thyroxine 4 (FT4), serum calcium (Ca), phosphate (P), alkaline phosphatase (ALP), parathyroid hormone (PTH).

All patients included in the study underwent both fasting blood glucose and oral glucose load tests. Glucose tolerance was classified into three categories based on
the fasting blood glucose level: I) fasting blood glucose < 100 mg/dL was considered normal; II) fasting blood glucose of 100 mg/dL and less than 126 mg/dL was defined as impaired fasting glucose; and III) a fasting blood glucose ≥126 mg/dL warranted the diagnosis of diabetes. Based on the oral glucose load test, impaired glucose tolerance was defined as a blood glucose level between 140 and < 200 mg/dL, and diabetes was defined as a glucose level ≥ 200 mg/ dL, 2 h after a 75-g oral glucose load. Individuals with impaired fasting glucose and/or impaired glucose tolerance were recently designated as prediabetic by the American Diabetes Association [19].

CBC was performed with a Celtac automated blood counter following calibration. HbA1C was assayed with a Misba i2 semi-automated device (Aggapy, India). Random blood glucose was estimated with a BT1500 fully automated chemistry analyzer (Biotechnica, Italy). Serum ferritin and thyroid hormones (FT3, FT4, and TSH) were measured by the Vitek Immuno Diagnostic Assay System (VIDAS- BioMerieux, France), an enzyme-linked fluorescent assay, according to the manufacturer’s instructions. Parathyroid hormone (PTH) was estimated with the IFlash1800 fully automated immunoassay system (Shenzhen Yhlo Biotech Co., Ltd.)

Primary overt hypothyroidism was diagnosed if FT3 was less than 2.50 pg/mL (normal range in children 2.50–4.64 pg/mL) or FT4 was less than 0.8 ng/dL (normal range in children 0.8–2 ng/dL) or both with high TSH over 6 mIU/ml (normal range 0.35–6 mIU/ml). Normal FT4 and FT3 and greater than normal TSH were considered evidence for subclinical hypothyroidism. Hypoparathyroidism was diagnosed if PTH was less than 15 pg/ml (normal range 15–65 pg/ml), hypocalcemia if less than 7 mg/dl (normal range 7–10 mg/dl), and hyperphosphatemia if more than 6.5 mg/dl (normal range 4.5–6.5 mg/dl). Increased alkaline phosphatase (ALP) if more than 450 U/L. (normal range 250 to 450 U/L).

**Statistical analysis**

Data were analyzed using STATA intercooled version 12.1. Quantitative data were represented as mean, standard deviation, median, and range. Data were analyzed using a Mann–Whitney test as the distribution was not normal. Qualitative data were presented as number and percentage and compared using either a chi-square test or Fisher’s exact test. A binary logistic regression model was used to calculate the odds ratio (OR), 95% confidence interval (CI), and P value of the risk factors of endocrine disorders. Results were considered significant at P < 0.05.

**Results**

Of 120 TM children, 54 (45%) patients were female and 66 (55%) were male. The mean (SD) patient age at the time of the study was 11.34 (2.27), range: 2–12 years and 11.12 (2.01) range: 2–12 in males and females, respectively. The mean (SD) duration of the disease was 5.74 (3.45) and 5.14 (3.20) in males and females, respectively. Patient’s anthropometric measurements, iron chelation therapy pattern and other patient characteristics are shown in Table 1.

Most of the patients had no endocrine disorders (92/120, 76.67%; Table 2). The presence of any endocrine disorder was observed in 28/120 (23.33%) patients. However, the most common endocrine disorders were thyroid disorders 11/120 (9.17%) (subclinical hypothyroidism 6/120 [5.00%] and clinical hypothyroidism and 5/120 [4.17%]), followed by abnormalities in glucose homeostasis 9/120 (7.5%), and none of them had diabetes mellitus (DM). The least common endocrine disorders seen in our patients was hypoparathyroidism in 8/120 (6.6%). Hypocalcemia was found in 7/120 (5.83%), hyperphosphatemia in 10/120 (8.33%), and increased alkaline phosphatase in 13/120 (10.8%).

As shown in Table 3, the presence of endocrine disorders in the studied population was not significantly associated with the risk factors age, gender, hemoglobin level before transfusion, or splenectomy status (P > 0.05). Moreover, there were no significant differences between the mean (SD) duration of TM in patients with endocrine disorders at 6.22 (1.20) years compared with non-endocrine disorders at 5.28 (2.64) years (OR 1.20, 95% CI 0.98:1.45, P = 0.07). However, there were a significant increase in the mean (SD) serum ferritin levels in the studied TM patients with endocrine disorders 3631.45 (1636) µg/L when compared with the studied TM patients without endocrine abnormalities 2658.40 (1443) µg/L (OR 0.98, 95% CI 0.96–0.99, P = 0.003).

Regarding iron chelating therapy, there were no significant change between patients with or without endocrine disorders regard monotherapy started with deferasirox or desferoxamine. However, in those who received combined therapy, 9 of 28 (32.14%) cases had endocrine disorders, compared with 50 of 92 (54.35%) cases who did not have endocrine disorders, (OR 0.40, 95% CI 0.16:0.97, P = 0.04; Table 3).

There were 84 of 120 (70%) cases who suffered from malnutrition with Z score < −2 for BMI; Table 1. However, there was no significant differences between TM in those who had endocrine disorders and those who did not have endocrine disorders regarding malnutrition (OR 0.47, 95% CI 0.19:1.14, (P = 0.09). We found poor compliance with iron chelating agents, in which 19 of 28 (67.86%) in the endocrine disorder group received less than 50% of the calculated doses per month, compared with 41 of 92 (44.57%) in the non-endocrine disorder group (OR 0.38, 95% CI 0.16:0.93, P = 0.03; Table 3).
The life expectancy of patients with TM has increased due to improved therapeutic options [5]. However, various complications such as endocrinopathies, cardiomyopathies, and bone disorders are still obstacles to treatment in these patients [4–6]. In the present study, we noted that endocrinopathies appear early in approximately one fourth of TM patients at the age of 12 years or younger. A high serum ferritin level is usually associated with increased endocrine disorders. Combined iron-chelating agents were associated with a decreased prevalence of endocrine disorders when compared with monotherapy.

In the present study, we report that an increased serum ferritin level is associated with increased

**Table 1** Patient's characteristics of study population

| Characteristics                                      | Summary statistics                      |
|------------------------------------------------------|-----------------------------------------|
|                                                      | Total 120 patients                      |
|                                                      | Male 66 (55%)                           |
|                                                      | Female 54 (45%)                         |
| Age / years                                          |                                        |
| Mean (SD)                                            | 11.34 (2.27)                            |
| Median (range)                                       | 11.12 (2.01)                            |
| Duration of disease/years                            |                                        |
| Mean (SD)                                            | 5.74 (3.45)                             |
| Weight (Kg) Mean (SD)                                | 5.14 (3.20)                             |
| Height (Cm) Mean (SD)                                | 28 (7.65)                               |
|                                                      | 25 (6.67)                               |
| Body mass index (BMI) kg/m²                           |                                        |
| Mean (SD)                                            | 16.82 (8.73)                            |
| Median (range)                                       | 16.62 (6.78)                            |
| Malnutrition according to Z score for BMI (percentage)| 44 (66.67%)                             |
|                                                      | 16 (74.07%)                             |
| Family history of thalassemia major                  |                                        |
| No                                                    | 26 (39.39%)                             |
| Yes                                                   | 40 (60.61%)                             |
| Family history of endocrine disorders                 |                                        |
| No                                                    | 41 (62.12%)                             |
| Yes                                                   | 25 (37.88%)                             |
| Ferritin level                                        |                                        |
| Mean (SD)                                            | 3121 (1390)                             |
| Median (range)                                       | 2997 (1480)                             |
| Hemoglobin level before transfusion (Gram/DL)        |                                        |
| Mean (SD)                                            | 6.82 (1.45)                             |
| Median (range)                                       | 6.65 (1.89)                             |
| Splenectomy                                           |                                        |
| No                                                    | 30 (45.45%)                             |
| Yes                                                   | 36 (54.55%)                             |
| Deferasirox (N. of patients)                          |                                        |
| No                                                    | 20 (30.30%)                             |
| Yes                                                   | 14 (21.22%)                             |
| Desferoxamine (N. of patients)                        |                                        |
| No                                                    | 32 (48.48%)                             |
| Yes                                                   | 27 (50%)                                |

**Table 2** The prevalence of endocrine disorders of studied population

| Diseases                         | Number120 cases (percentage)          |
|----------------------------------|---------------------------------------|
| No endocrine disorders           | 92 (76.67%)                           |
| Impaired glucose tolerance (IGT)| 5 (4.17%)                              |
| Impaired fasting glucose (IFG)   | 4 (3.33%)                              |
| Diabetes mellitus (DM)           | 0 (00%)                               |
| Subclinical hypothyroidism       | 6 (5.00%)                              |
| Clinical hypothyroidism          | 5 (4.17%)                              |
| Hypoparathyroidism               | 8 (6.66%)                              |

**Discussion**

The life expectancy of patients with TM has increased due to improved therapeutic options [5]. However, various complications such as endocrinopathies, cardiomyopathies, and bone disorders are still obstacles to treatment in these patients [4–6]. In the present study, we noted that endocrinopathies appear early in approximately one fourth of TM patients at the age of 12 years or younger. A high serum ferritin level is usually associated with increased endocrinopathies. Combined iron-chelating agents were associated with a decreased prevalence of endocrine disorders when compared with monotherapy.

In the present study, we report that an increased serum ferritin level is associated with increased
endocrine disorders in TM patients. A high prevalence of endocrine abnormalities in TM patients associated with increased iron overload was previously reported [3, 5, 10, 20]. However, other reports did not find a significant relationship between endocrine disorders and serum ferritin level [21, 22]. The serum ferritin level could estimate the liver iron concentration in TM [23]. Moreover, Sobhani et al. [24] found that higher serum ferritin strongly predicted the severity of cardiac and liver iron overload.

In this study, two thirds of the cases had malnutrition. We defined malnutrition according to WHO definition by Z score for BMI if < −2, which was the most accepted definition worldwide [18]. Our cases’ BMIs were compatible with those reported by Biswas et al. [25], who studied 328 TM patients, approximately 37.2% of which were between 11 and 12 years of age. They found that 48.2% were malnourished with a mean BMI of 13.9 ± 1.6 kg/m². TM has a significant impact on the growth process of children, and hence early intervention is needed to reduce the prevalence of malnutrition as good nutrition with adequate vitamin and trace element intake, along with calcium and vitamin D supplementation, side by side with optimal iron chelating therapy [26].

Early diagnosis and treatment of TM complications are essential to ensure a good quality of life and to

| Table 3 Risk factors of endocrine disorders in young children with thalassemia major |
|----------------------------------|-------------------------------|------------------------------|-----------------|-----------------|
| Age mean (SD)                    | Endocrine disorder (28/120)  | No endocrine disorder (92/120) | Odds ratio (95% confidence interval) | P value |
|                                  | 11.60 (3.21)                  | 11.01 (1.27)                  | 1.33 (0.48:2.21) | 0.90 |
| Gender                           |                               |                              |                               |      |
| Females                          | 12 (42.86%)                   | 42 (45.65%)                  | 1                             |      |
| Males                            | 16 (57.14%)                   | 50 (54.35%)                  | 1.12 (0.48:2.63) | 0.80 |
| Duration of the disease/years Mean (SD) | 6.22 (1.20)                  | 5.28 (2.64)                  | 1.20 (0.98:1.45) | 0.07 |
| Malnutrition                     |                               |                              |                               |      |
| No                               | 12 (42.86%)                   | 24 (26.09%)                  | 1                             |      |
| Yes                              | 16 (57.14%)                   | 68 (73.91)                   | 0.47 (0.19:1.14) | 0.09 |
| Hemoglobin level before blood transfusion (Gram/DL) Mean (SD) | 7.12 (1.62)                  | 6.69 (1.89)                  | 1.14 (0.90:1.46) | 0.29 |
| Splenectomy                      |                               |                              |                               |      |
| No                               | 13 (46.43%)                   | 52 (56.52%)                  | 1                             |      |
| Yes                              | 15 (53.57%)                   | 40 (43.48%)                  | 1.50 (0.64:3.50) | 0.35 |
| Family history of thalassemia major |                               |                              |                               |      |
| No                               | 13 (46.43%)                   | 33 (35.87%)                  | 1                             |      |
| Yes                              | 15 (53.57%)                   | 59 (64.13%)                  | 0.64 (0.27:1.51) | 0.65 |
| Family history of endocrine disorders |                               |                              |                               |      |
| No                               | 15 (53.57%)                   | 58 (63.04%)                  | 1                             |      |
| Yes                              | 13 (46.43%)                   | 34 (36.96%)                  | 1.48 (0.63:3.48) | 0.37 |
| Ferritin level Mean (SD)         | 3631.45 (1636)                | 2658.40 (1443)               | 0.98 (0.96–0.99) | 0.003 |
| Deferasirox                      |                               |                              |                               |      |
| No                               | 16 (57.14%)                   | 68 (73.91%)                  | 1                             |      |
| Yes                              | 12 (42.86%)                   | 24 (26.09%)                  | 2.13 (0.88:5.13) | 0.09 |
| Desferoxamine                    |                               |                              |                               |      |
| No                               | 21 (75.00%)                   | 74 (80.43%)                  | 1                             |      |
| Yes                              | 7 (25.00%)                    | 18 (19.57%)                  | 1.37 (0.50:3.72) | 0.54 |
| Combined therapy                 |                               |                              |                               |      |
| No                               | 19 (67.86%)                   | 42 (45.65%)                  | 1                             |      |
| Yes                              | 9 (32.14%)                    | 50 (54.35%)                  | 0.40 (0.16:0.97) | 0.04 |
| Compliance to medication         |                               |                              |                               |      |
| Received ≤50%/month              | 19 (67.86%)                   | 41 (44.57%)                  | 1                             |      |
| Received > 50%/month             | 9 (32.14%)                    | 51 (55.43%)                  | 0.38 (0.16:0.93) | 0.03 |

P value was obtained from univariate logistic regression
reduce early morbidity and mortality. In TM patients with endocrine disorders, sometime early therapy is recommended in the form of thyroxine therapy. An improvement of subclinical hypothyroidism and primary hypothyroidism has been observed after intensive iron chelation therapy [17]. Therefore, from these data, periodic assessment of iron overload and follow-up of endocrine functions beside improved adherence to chelation therapy should be strongly considered in hospitals in which there are no electronic files or routine follow up of these patients, in order to improve their quality of life and life expectancy.

Iron chelation therapy is the only method of iron overload control in transfusion-dependent patients. In the present study, we found that oral deferasirox is not superior to deferoxamine when used as monotherapy. These data not agree with other reports [27, 28] showing that long-term oral deferasirox therapy may decrease the prevalence of endocrinopathies in TM. The main explanation for this may be the short duration of therapy in our study and the different age groups. However, in our study, combined therapy was associated with a decreased incidence of endocrine disorders, similar to data previously reported by Farmaki et al. [16]. Moreover, Ho et al. [29] found that combined therapy with deferoxamine and oral deferasirox improved clinical outcomes and quality of life in terms of iron chelation in transfusion-dependent patients with TM at a reasonable cost from a healthcare perspective. The TM patients in the present study had poor compliance to iron-chelating medication; this could explain the occurrence of early endocrine disorders. A similar result was previously reported by Sobhani et al. [24], who found that irregular use of chelating drugs was associated with a higher risk of iron tissue damage, regardless of the type of chelating agent.

In young children and adults, type 2 diabetes develops over a long period of time, often presenting initially as a pre-diabetic state such as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Prediabetes raises the short-term absolute risk of type 2 diabetes by 3-to 10-fold, with some populations exhibiting greater risk than others [30]. Furthermore, pre-diabetic states are also at increased risk of cardiovascular disease [31]. Endocrine abnormalities should be monitored carefully, and a thorough endocrine evaluation should be carried out yearly in every patient with TM to detect subclinical endocrinopathies [26]. Early identification and treatment of persons with prediabetes has the potential to reduce or delay the progression to diabetes [32].

The total prevalence of abnormal glucose homeostasis in the present study was 7.50%, which could be divided into impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and DM of 5 (4.17%), 4 (3.33%), and 0 (0%), respectively. In previous reports, the prevalence of DM was reported to vary between 0.00% [33] and 26.70% [20]. In a meta-analysis conducted by He LN et al. [34] including 35 studies, it was revealed that the prevalence of IGT, IFG, and DM in TM were 12.46, 17.21%, and 6.54, respectively, in patients aged from 2 to 28 years. The increased prevalence of abnormal glucose homeostasis in the previous meta-analysis [34] could be due to the different age groups. The prevalence of abnormal glucose homeostasis in TM was higher compared to that in non-TM children and young adults, which was 8–17 per 100,000 per year in one cohort [35].

We reported thyroid disorder in the present study at a rate of 9.17%. However, the overall prevalence of hypothyroidism in TM is variable between studies with different age groups; it was (14.6%) in Iran [36] and 21.6% in Italy [37]. Different results could be due to genetic, geographical, cultural, and economic factors and also due to the quality of blood transfusions and chelators. Our data demonstrated that the prevalence of hypothyroidism (9.17%) increased in TM patients when compared with non-TM children with sufficient dietary iodine, in which only 0.3–0.4% of children had hypothyroidism, and approximately 4.3–8.5% had subclinical hypothyroidism [38]. Moreover, the prevalence of hypoparathyroidism in our study was (6.6%) which is comparable with that in other studies with different age groups. In Saffari et al. [13] in TM patients with a mean (SD) age 21.26 ± 4.53 years, the prevalence of hypoparathyroidism was 7.79%, and in De Sanctis et al. [37] in TM patients with the mean age less than 16 years, the prevalence of hypoparathyroidism was 6.9%.

In our study, we tried to detect endocrine disorders in young age children with TM. However, we did not find any relationship between the duration of TM and endocrine disorders. This could be explained by other factor such as serum ferritin level and patient compliance with chelating therapy having a greater role than disease duration. Furthermore, we did not find a relationship between children with and without endocrine disorders in relation to family history of TM, family history of endocrine disorders, splenectomy, gender, or hemoglobin level before transfusion, in agreement with previously published studies [10, 20].

The presented study had some limitations; liver iron concentration determined by noninvasiv magnetic resonance imaging relaxation time techniques was used to estimate body iron load and has been shown to predict total body iron stores more accurately than the serum ferritin level in some reports [39–41]. In this study, we measured iron overload from the serum ferritin level as liver iron concentration measurement was not available in our unit. We did not perform a follow up for the cases, as the purpose of this cross-sectional study was to
take a picture of the prevalence of endocrinopathies and the risk factors associated with them in this population. We selected this age group because older age groups had already been studied extensively. Serial measurements of other endocrine functions such as growth hormone, reproductive hormones, and adrenal hormones in TM patients, needed in further studies.

Conclusion
We recommended that endocrine evaluation in thalassemic patients be carried out routinely, even at a younger age, especially in patients with iron overload and poor compliance with chelating therapy, particularly for glucose homeostasis, hypothyroidism, and hypoparathyroidism. One fourth of studied patients had endocrine disorders, which were related to high serum ferritin levels. We reported that oral deferasirox is not superior to deferoxamine when used as monotherapy. However, combined iron-chelating agents were associated with a decreased prevalence of endocrine disorders when compared with monotherapy.

Abbreviations
ALP: Alkaline phosphatase; BMI: Body mass index; Ca: Serum calcium; CBC: Complete blood count; CI: Confident interval; DM: Diabetes mellitus; FT3: Free thyroxine 3; FT4: Free thyroxine 4; HbA1C: Glycosylated hemoglobin; IFG: Impaired fasting glycose; IGT: Impaired glycose tolerance; M: Male; TM: Thalassemia major; TSH: Thyroid stimulating hormone; WHO: World health organization

Acknowledgements
The authors thank http://proof-reading-services.com for language editing.

Authors’ contributions
RAM are responsible for the study design, collection and interpretation of the data, manuscript writing, and statistical analysis. AK performed laboratory investigations, collection and interpretation of the data, participated drafting the manuscript, and statistical analysis. MSF interpretation of the data, manuscript writing, and statistical analysis. AK performed laboratory investigations, collection and interpretation of the data, participated drafting the manuscript. All authors reviewed and approved the final manuscript for publication.

Funding
The authors received no funding to perform this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The research related to human subject use complied with all the relevant national regulations and institutional policies. Local ethical approval for the study was obtained from the Research Committee of the Faculty of Medicine at Sohag University, Egypt (Number 612, 2017). Written informed consent was obtained from all parents of the participating children.

Consent for publication
The authors declare that they have obtained the consent for publication from each parent’s patient.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Paediatrics, Faculty of Medicine, Sohag University, Sohag 82524, Egypt. 2Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt. 3Department of Haematology and Clinical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt.

Received: 8 February 2021 Accepted: 15 July 2021 Published online: 31 July 2021

References
1. Patrinos GP, Kolla P, Papadakis MN. Molecular diagnosis of inherited disorder: lessons from hemoglobinopathies. Hum Mutat. 2005;26(5):399–412. https://doi.org/10.1002/humu.20225.
2. Montzer WC, Kan YW. Prospects for research in hematologic disorders: sickle cell disease and thalassemia. JAMA. 2001;285(5):640–2. https://doi.org/10.1001/jama.285.5.640.
3. El-Beshlawy A, Kadham N, Rajeb L, Hussein I, Mouktar G, Moustafa A, et al. Thalassemia prevalence and status in Egypt. Pediatr Res. 1999;45:760. https://doi.org/10.1203/00006450-199905010-00132.
4. Viprakasit V, Lee-Lee C, Chong QT, Lin K-H, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol. 2009;90(4):435–45. https://doi.org/10.1007/s12185-009-0432-0.
5. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol. 2005;42(2):S14–8. https://doi.org/10.1053/j.seminhematol.2005.01.004.
6. Gomez S, Dabas A, Bagmar S, Madhu SV. Glycose homeostasis and effect of chelation on beta cell function in children with beta-thalassemia major. J Pediatr Hematol Oncol. 2018;40(1):56–9. https://doi.org/10.1097/MPH.0000000000001043.
7. Taheri AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(11):1886–92. https://doi.org/10.1182/blood-2009-09-243154.
8. Li CK, Chik KW, Wong GWK, Cheng PS, Lee V, Shing MMK. Growth and endocrine function following bone marrow transplantation for thalassemia major. Pediatr Hematol Oncol. 2004;21(5):397–402. https://doi.org/10.1007/s10065-004-0008-6.
9. Breda L, Gambari R, Rivella S. Gene therapy in thalassemia and hemoglobinopathies. Mediterr J Hematol Infect Dis. 2009;1(1):e2009008.
10. Perera N, Lau N, Mathews S, Waite C, Ho P, Caterson I. Overview of endocrinopathies associated with beta-thalassemia major. Intern Med J. 2010;40(10):689–96. https://doi.org/10.1111/j.1445-5994.2010.02254.x.
11. Hejazi S, Safari O, Arjmand R, Qorbani M, Safari A, et al. Effect of combined versus monotherapy with deferoxamine and deferiprone in iron overloaded thalassemia patients: a randomized clinical trial. Int J Pediatr. 2016;4(1):959–65.
12. Skarmoutsou C, Papassotiriou I, Traeger-Synodinos J, Stamou H, Ladis V, Metaxotou-Mavrommati A, et al. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hba (2) levels. Haematologica. 2003;88(6):631–6.
13. Saffari F, Mahyar A, Jalilogladi S. Endocrine and metabolic disorders in beta-thalassemia major patients. Caspian J Intern Med. 2012;3(3):466–72.
14. Chakravart C, Norouzi S, Farzad M, Ghafar F. Endocrine disorders in beta thalassemia major patients. Int J Pediatr. 2017;5:5531–8.
15. Najafipour F, Aliagaramazadeh A, Aghamohammazadeh N, Bahrami A, Mobsari M, Naifar M, et al. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major. Ann Saudi Med. 2008;28(5):361–6. https://doi.org/10.1111/j.1349-0916.2008.01975.x.
16. Farmaki K, Tzoumari I, Pappa C, Chouliras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassemia major. Br J Haematol. 2010;148(3):466–75. https://doi.org/10.1111/j.1365-2447.2009.07970.x.
17. De Sanctis V, Soliman AT, Canatan D, Yassin MA, Dar S, Elsheidy H, et al. Thyroid disorders in homozygous beta-thalassemia: current knowledge, emerging issues and open problems. Mediterr J Hematol Infect Dis. 2019;11(1):e2019029. https://doi.org/10.4084/mjhid.2019.029.
18. WHO Multicentre Growth Reference Study Group. WHO child growth standards based on length/height, weight and body mass index for age. Acta Paediatr. 2006;95(6):785–95.
19. No authors listed. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol. 1995;42:581–6.
20. Mula-Abed W-A, Al Hashmi H, Al Muslahi M, Al Muslahi H, Al LM. Prevalence of endocrinopathies in patients with beta-thalassaemia major—a cross-sectional study in Oman. Oman Med J. 2008;23(4):257–62.
21. Shahriari M, Sadjadian N. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran. East Mediterr Health J. 2003;9:55–60.
22. Sabato A, De Sanctis V, Atti G, Capra L, Bagni B, Vullo C. Primary hypothyroidism and the low T3 syndrome in thalassaemia major. Arch Dis Child. 1983;58(2):120–7. https://doi.org/10.1136/adc.58.2.120.
23. Al-Momen H, Jasim SK, Hassan QA, Al HI. Relationship between liver iron concentration determined by R2-MR, serum ferritin, and liver enzymes in patients with thalassemia intermedia. Blood Res. 2018;53(4):314–9. https://doi.org/10.5094/br.2018.53.4.314.
24. Sobbani S, Rahmani F, Rahmani M, Askari M, Kompani F. Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassaemia: a cross-sectional study. Croat Med J. 2019;60(5):405–13. https://doi.org/10.3325/cmj.2019.60.405.
25. Biswas B, Naskar NN, Basu K, Dasgupta A, Basu R, Paul B. Malnutrition, its attributes, and impact on quality of life: an epidemiological study among B-thalassemia major children. Korean J Fam Med. 2021;42(1):66–72. https://doi.org/10.4092/kjfm.2019.0066.
26. Dey P, Konwar G, Sarkar B. Body mass index in thalassemia children. J Evol Med Dent Sci. 2019;8(1):1537–40. https://doi.org/10.14260/jemds.2019.341.
27. Bilgin BK, Yozgat AK, Isik P, Çulha V, Kacar D, Kara A, et al. The effect of deferasirox on endocrine complications in children with thalassemia. Pediatr Hematol Oncol. 2020;37(6):455–64. https://doi.org/10.1080/08880018.2020.1734124.
28. Casale M, Citarella S, Filosa A, De Michele E, Palmieri F, Ragozzino A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with B-thalassemia major. Am J Hematol. 2014;89(12):1102–6. https://doi.org/10.1002/ajh.23844.
29. Ho WL, Chung K-P, Yang S-S, Lu M-Y, Jou S-T, Chang H-H, et al. A pharma-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. J Formos Med Assoc. 2013;112(4):221–9. https://doi.org/10.1016/j.jfma.2011.08.020.
30. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–35. https://doi.org/10.1089/thy.2012.0205.
31. Angelucci E, Bittener GM, McAleney CE, Ripalti M, Barociani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327–31. https://doi.org/10.1056/NEJM200008033430503.
32. St Pierre TG, Clark PR, Chua-anusom W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855–61. https://doi.org/10.1182/blood-2004-01-0177.
33. Wood JC, Enriquez C, Ghugre N, Tsyka JM, Carson S, Nelson MD, et al. MR R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460–5. https://doi.org/10.1182/blood-2004-10-3982.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.